Ken15
Active member
- Joined
- Jan 9, 2018
- Messages
- 76
- Reason
- Lost a loved one
- Diagnosis
- 09/2017
- Country
- US
- State
- SC
- City
- Hilton Head Island
Published today in ALS News Today
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Apic Bio‘s APB-102, an investigational gene therapy aiming to treat familial amyotrophic lateral sclerosis (ALS) associated with mutations in the superoxide dismutase 1 (SOD1) gene.
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Apic Bio‘s APB-102, an investigational gene therapy aiming to treat familial amyotrophic lateral sclerosis (ALS) associated with mutations in the superoxide dismutase 1 (SOD1) gene.
